Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 206.84

+3.8%

Nov 24 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Peter Singleton who wrote (14012)	1/31/1998 7:13:00 PM
From: Cacaito	Read Replies (2) of 32384

Aronex's Atragen is a lipid based intravenous formulation. It is designed to decrease side effects of oral transretinoic acid (the oral non lipid version is already approved by FDA). Panretin is a new generation drug, oral and with minimal side effects. It should be less expensive, and less cumbersome than Atragen. Especially in Kaposi's (both drugs aim to this market too), Panretin gel form is even of greater advantage. Not only there is a decrease on side effects, but also a very important decrease in drug interactions, since this patients are in multidrug regimen. Panretin is much more advanced in development, Ligand is a better financed company. Aronex only interesting product is Zintevir (integrase inhibitor)for HIV, recently they got some money from the NIH to start a phase I study. Even if succesful, at least two to four years more for development. They have a website: www.aronex.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next